for use with measles vaccine (0-4-0-8 IU/kg body weight; Blood Products Laboratory) was given in the opposite arm with a separate syringe immediately after the vaccine was injected. The measles haemagglutination inhibition antibody response was estimated in the paired sera by MC as described previously.4
reactions were reported.
Discussion
The 45 children in this study undoubtedly required protection from measles and because of their personal history were considered at risk of having a convulsion from a febrile response to the vaccine given alone. The one fit reported was not associated with fever and occurred in a child with a grossly abnormal brain. Clearly in this small study no unacceptable reactions occurred despite the increased risk.
Since it is not justifiable to take two blood samples from children routinely given measles vaccine any comparison of antibody response must be made with results from an earlier study. In a Medical Research Council trial in 1964, 75 children aged 10 months to 2 years were bled before and after being given Schwarz strain vaccine. The response to the vaccine without immunoglobulin was significantly higher (5% level or beyond), confirming that the antibody response is modified by immunoglobulin. All but one of the children in our study, however, produced a response; only clinical follow up will determine protection.
Modifying possible febrile reactions to further attenuated vaccines by using immunoglobulin is not considered necessary outside Britain. Nevertheless, if the current recommendation results in the vaccination ofchildren such as these it seems justified, since without it they would have remained unvaccinated and at risk. Prednisolone was given in doses of 0-2, 04, and 0-6 mg/kg body weight daily for two weeks in a double blind randomised order (equivalent to 14, 28, and 42 mg of prednisolone daily in a person weighing 70 kg). Patients developing an exacerbation recorded peak expiratory flow rate twice daily for two days before starting and two weeks during treatment. A dose response was shown that was significant for the difference between the peak flows, low dose<medium dose (p<0-005), medium dose<high dose (p<O-OOl) at the end of treatment.
Introduction
The value of treatment with corticosteroids in patients with asthma was first reported in 1949.' There followed similar uncontrolled reports confirming their short term value. The Medical Research Council (MRC) published two controlled studies in 195623; in one corticosteroid treatment for acute severe asthma was beneficial, but the second trial of treatment for chronic asthma over a period of six months showed that long term treatment with oral corticosteroids conferred no advantage. Other reports, however, showed that oral Patients and methods A randomised double blind study was performed giving three different doses of oral corticosteroids to each patient during three separate exacerbations of their asthma. The doses used were 0-2, 0-4, and 0-6 mg prednisolone/kg body weight as a single morning dose daily for two weeks (equivalent to 14, 28, and 42 mg prednisolone in a 70 kg person). The three courses of prednisolone looked identical to the patient and consisted of varying combinations of active and placebo tablets, which the pharmacist prepared on the basis of the patient's weight.
Patients kept a Wright mini peak flow meter at home and began recording their peak expiratory flow rate whenever they began to experience an exacerbation. An exacerbation was arbitrarily defined as an increase in symptoms despite increased use of inhaled P2 stimulants accompanied by a drop in their usual peak flow rates. Patients recorded peak expiratory flow rates twice daily, first thing in the morning after getting out of bed and last thing at night before going to bed. Patients contacted me at the start of an exacerbation and were seen soon afterwards. A course of corticosteroids was prescribed if the exacerbation was thought to warrant treatment with corticosteroids. The patients continued to record their peak expiratory flow rate for the two weeks' duration of treatment. The patients had at least two days' recordings of peak expiratory flow rates before they began treatment with corticosteroids.
All patients were treated with inhaled salbutamol 200 .tg four times daily, and the dose was boosted to 200 xg two hourly if required. Two patients were taking low dose beclomethasone dipropionate 0-4 mg/day and two others slow release aminophylline preparations.
Results
Details of the patients are given in table I and show that eight of the patients had asthma of late onset (age at onset >45 years). Table II shows the individual peak expiratory flow rates before and over the last four days of treatment for the three treatments. There were no significant differences in morning or evening peak expiratory flow rate for all patients before receiving the three doses of prednisolone.
The figure gives the results, expressed as the mean peak expiratory flow rate for the group of 10 patients; both the morning and evening peak expiratory flow rates for the three doses ofprednisolone are given. By the end of the treatment period a dose response effect became apparent. Over the last four days all peak expiratory flow rates for the medium dose (0 4 mg/kg body I ). weight) were higher than the values for the low dose (0 2 mg/kg) and all the high dose (0-6 mg/kg) peak expiratory flow rates were higher than those for the medium dose (table III). These differences were significant for the morning and evening peak expiratory flow rates combined and for the morning peak expiratory flow rate alone but did not reach significance for the evening peak expiratory flow rate, over the last four days.
All peak expiratory flow rates during the three treatments showed a similar pattern of diurnal variation, all the morning peak expiratory flow rates are represented by the trough values and the evening peak expiratory flow rates by peak values. There was a trend towards improvement throughout the two week treatment period, and in none of the six graphs does an obvious plateau occur, though the graphs for high dose peak expiratory flow rate do show a trend towards a plateau of response over the last four days of treatment.
The individual responses were assessed by inspecting the peak expiratory flow rate graphs for all 30 treatments (10 patients each having three treatments). The time taken to reach a plateau of response was assessed by eye in all cases, and in three courses a plateau was not obviously reached by the end of treatment. The mean time taken to reach a plateau at all three doses was virtually identical, at 10-2 days for low dose treatment, 10-2 days for medium dose, and 10-0 days for high dose (the time taken to reach a plateau in the three cases in which a plateau was not actually achieved was taken to be 14 days).
Discussion
Ethical considerations and a proved dose response effect obviate the need for a control group and show that treatment with corticosteroids were of value in this group of patients.
This study did not show the dose required to produce the maximum effect-that is, the top end of the dose response curve. Britton et al showed in patients with severe acute asthma that there is no advantage in using a dose greater than 80 mg prednisolone daily for seven days with a reduction to 60 mg daily for three days.9 As the pharmacokinetics of prednisolone are dose dependent but not linear it is necessary to more than double the dose to achieve twice the effect.'0 The top end of the dose response curve probably lies between 40 mg and 80 mg daily (about 0-6 mg/kg body weight and 1X2 mg/kg), and in view of the above comments on the pharmacokinetics is probably nearer 40 mg. The mechanism of action of corticosteroid treatment in asthma is poorly understood, but it may be possible to extrapolate from the results of use of prednisolone in immune suppression after renal transplantation. Papadakis et al showed that 0-6 mg prednisolone/kg body weight was just as effective as much higher doses of corticosteroids for preventing the rejection of cadaveric kidneys."
Although the group data did not clearly show a plateau, analysis of the individual data suggests that a plateau had been reached by 14 days' treatment as a plateau was seen by eye in 27 of the 30 courses. The duration of treatment in this study was too short to showuif a plateau of response had or had not occurred in three of the courses of treatment. The average duration of 10 days to achieve a plateau for all three doses suggests that the time course is not dose dependent. The time course of the response is probably dependent on the clinical state of the patient, patients with exacerbations of chronic asthma requiring more time to achieve a maximum response than the same patients during remission. This is supported by findings of a previous study, which showed the time course of the response to oral corticosteroid treatment in patients with chronic airflow obstruction who were not experiencing an exacerbation. '2 The results for thefgroup showed a plateau occurring at eight days, and the average duration of response was 5 1 days (calculated from Webb and Clark'2).
The absolute diurnal variation did not alter significantly over the two weeks' treatment (figure). The improvement in morning peak expiratory flow rate paralleled the improvement in evening peak expiratory flow rate so that the absolute morning dip improved but diurnal variation did not. Munch et al showed that nocturnal symptoms improve with regular inhaled steroids,'3 and this study supports their findings.
Prednisolone was given as a single morning dose rather than in divided doses, two, three, or four times daily for three reasons.'°F irstly, the plasma half life of the prednisolondis 2-3 hours and a morning dose coincides with peak activities of circulating adrenocorticotrophic hormone, thus inhibition of this hormone is minimised. Secondly, the biological half life of prednisolone is 24-36 hours, which suggests that a dose given more often than once daily is unnecessary. Finally, the 'protein binding capacity-of transcortin, the steroid&carrier protein, is weakest during the day, resulting in high concentrations of free unbound steroid.
The practice of tailing off corticosteroid treatment was introduced in the mid-195Os,'4 and is still widely practised. This was presumably thought to aid the recovery of the hypothalamicpituitary-adrenal axis and to prevent any rebound increase in asthma. There is no-supportive evidence that a short course ofhigh dose corticosteroids causes clinically significant depression in the hypothalamic-pituitary-adrenal axis" or that there is any rebound phenomenon after a short high dose course of corticosteroids. It seems more sensible to administer a dose oforal corticosteroids that has a maximum effect and to continue treatment at that dose until the patient has reached a plateau of improvement.
In conclusion, a short high dose course of corticosteroids should usually consist ofa minimum dose of0-6 mg/kg body weight/day for a period of up to two weeks.
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